Krishna K. Rathnam

Meenakshi Mission Hospital & Research Centre, 625 107, 
Madurai, TN, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Meenakshi Mission Hospital & Research Centre, 625 107, 
Madurai, TN, IN 
OverviewLocationsClinical Research

Overview

Krishna Rathnam practices in Madurai, India. Their top areas of expertise are Xeroderma Pigmentosum, Triple-Negative Breast Cancer, Breast Cancer, and Orchiectomy.

Their clinical research consists of co-authoring 11 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Meenakshi Mission Hospital & Research Centre, 625 107, Madurai, TN, India
Other Locations
BMCHRC
Jaipur, RJ, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 1 Less Clinical Trial

11 Total Publications

Xenobiotic metabolizing gene polymorphisms and their influence on ovarian cancer susceptibility: A Case-Control and an in silico approach.
Xenobiotic metabolizing gene polymorphisms and their influence on ovarian cancer susceptibility: A Case-Control and an in silico approach.
Journal: Molecular biology reports
Published: May 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Rathnam's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile